Tumor Biology

, Volume 36, Issue 4, pp 2667–2674 | Cite as

Investigation of the role of 8-OHdG and oxidative stress in papillary thyroid carcinoma

  • Suzan Tabur
  • Şefika Nur Aksoy
  • Hakan Korkmaz
  • Mesut Ozkaya
  • Nurten Aksoy
  • Ersin Akarsu
Research Article

Abstract

The aim of this study was to determine levels of serum 8-hydroxy-2′-deoxyguanosine (8-OHdG) as an indicator of oxidant-induced DNA damage and oxidant status in patients with papillary thyroid carcinoma before and after surgery. This study included 25 patients with papillary thyroid carcinoma and age-matched 27 healthy controls. Total antioxidant status (TAS), total oxidant status (TOS), lipid hydroperoxide (LOOH), and 8-OHdG levels were measured. 8-OHdG levels were significantly higher in the preoperative papillary thyroid carcinoma (PTC) group compared with the healthy control group (p < 0.001) and were significantly lower after operation in patients with papillary thyroid carcinoma (p = 0.004). Oxidative stress index (OSI) levels were significantly higher in both preoperative and postoperative PTC patients compared with the healthy control group (p < 0.001 and p < 0.001, respectively). TOS levels were higher in the preoperative and postoperative PTC groups compared to the healthy control group (p < 0.001 and p < 0.001, respectively). TAS levels was lower in the preoperative PTC groups compared to the healthy control group (p = 0.011). Serum LOOH levels were higher in both preoperative and postoperative PTC groups compared to the healthy control group (p < 0.001 and p < 0.001, respectively). Correlation analysis yielded that serum 8-OHdG levels were positively correlated with OSİ and LOOH levels in patients with PTC before surgery (r = 0.668, p < 0.001; r = 0.446, p = 0.025, respectively) and had a negative correlation with TAS levels (r = −0.616, p = 0.001). We have shown severe oxidative DNA damage and impaired antioxidant status in papillary thyroid carcinoma.

Keywords

Papillary thyroid carcinoma Oxidative damage Lipid hydroperoxide (LOOH) Total antioxidant status (TAS) Total oxidant status (TOS) 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Sprague BL, Warren AS, Trentham-Dietz A. Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Cases Control. 2008;19:585–93.CrossRefGoogle Scholar
  3. 3.
    Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Chan AC, Lang BH, Wong KP. The pros and cons of routine central compartment neck dissection for clinically nodal negative (cN0) papillary thyroid cancer. Gland Surg. 2013;2(4):186–95.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Maier J, van Steeg H, van Oostrom C, Karger S, Paschke R, Krohn K. Deoxyribonucleic acid damage and spontaneous mutagenesis in the thyroid gland of rats and mice. Endocrinology. 2006;147(7):3391–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Beckman RA, Loeb LA. Genetic instability in cancer: theory and experiment. Semin Cancer Biol. 2005;15(6):423–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Paschke R. Molecular pathogenesis of nodular goiter. Langenbecks Arch Surg. 2011;396(8):1127–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Minuz P, Fava C, Cominacini L. Oxidative stress, antioxidants, and vascular damage. Br J Clin Pharmacol. 2006;61(6):774–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004;266(1–2):37–56.CrossRefPubMedGoogle Scholar
  10. 10.
    Chow E, Thirlwell C, Macrae F, Lipton L. Colorectal cancer and inherited mutations in base-excision repair. Lancet Oncol. 2004;5(10):600–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Himmetoglu S, Dincer Y, Ersoy YE, Bayraktar B, Celik V, Akcay T. DNA oxidation and antioxidant status in breast cancer. J Investig Med. 2009;57(6):720–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Arsova-Sarafinovska Z, Eken A, Matevska N, Erdem O, Sayal A, Savaser A, et al. Increased oxidative/nitrosative stress and decreased antioxidant enzyme activities in prostate cancer. Clin Biochem. 2009;42(12):1228–35.CrossRefPubMedGoogle Scholar
  13. 13.
    Gönenç A, Hacışevki A, Aslan S, Torun M, Şimşek B. Increased oxidative DNA damage and impaired antioxidant defense system in patients with gastrointestinal cancer. Eur J Intern Med. 2012;23(4):350–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Bulut M, Selek S, Bez Y, Karababa IF, Kaya MC, Gunes M, et al. Reduced PON1 enzymatic activity and increased lipid hydroperoxide levels that point out oxidative stress in generalized anxiety disorder. J Affect Disord. 2013;150(3):829–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res. 1998;39(8):1529–42.PubMedGoogle Scholar
  16. 16.
    Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83(5):1012–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103–11.CrossRefPubMedGoogle Scholar
  18. 18.
    Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37(2):112–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Arab K, Steghens JP. Serum lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem. 2004;325:158–63.CrossRefPubMedGoogle Scholar
  20. 20.
    Aycicek A, Erel O, Kocyigit A. Increased oxidative stress in infants exposed to passive smoking. Eur J Pediatr. 2005;164:775–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Nourooz-Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999;300:58–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Ceylan MF, Guney E, Alisik M, Ergin M, Dinc GS, Goker Z, et al. Lipid peroxidation markers in children with anxiety disorders and their diagnostic implications. Redox Rep. 2014;19(2):92–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Pande D, Negi R, Karki K, Khanna S, Khanna RS, Khanna HD. Oxidative damage markers as possible discriminatory biomarkers in breast carcinoma. Transl Res. 2012;160(6):411–8. Google Scholar
  24. 24.
    Diakowska D, Lewandowski A, Kopeć W, Diakowski W, Chrzanowska T. Oxidative DNA damage and total antioxidant status in serum of patients with esophageal squamous cell carcinoma. Hepatogastroenterology. 2007;54(78):1701–4.PubMedGoogle Scholar
  25. 25.
    Pande D, Negi R, Karki K, Khanna S, Khanna RS, Khanna HD. Oxidative damage markers as possible discriminatory biomarkers in breast carcinoma. Transl Res. 2012;160(6):411–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Płachetka A, Adamek B, Strzelczyk JK, Krakowczyk Ł, Migula P, Nowak P, et al. 8-Hydroxy-2′-deoxyguanosine in colorectal adenocarcinoma—is it a result of oxidative stress? Med Sci Monit. 2013;21(19):690–5.Google Scholar
  27. 27.
    Kosova F, Temeltaş G, Arı Z, Lekili M. Possible relations between oxidative damage and apoptosis in benign prostate hyperplasia and prostate cancer patients. Tumour Biol. 2014;35(5):4295–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Young O, Crotty T, O’Connell R, O’Sullivan J, Curran AJ. Levels of oxidative damage and lipid peroxidation in thyroid neoplasia. Head Neck. 2010;32(6):750–6.PubMedGoogle Scholar
  29. 29.
    Sharma A, Rajappa M, Saxena A, Sharma M. Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. Br J Biomed Sci. 2007;64(1):23–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Karki K, Pande D, Negi R, Khanna S, Khanna RS, Khanna HD. Expression of serum toll-like receptor 9 and oxidative damage markers in benign and malignant breast diseases. DNA Cell Biol. 2014;33(9):630–6.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Suzan Tabur
    • 1
  • Şefika Nur Aksoy
    • 2
  • Hakan Korkmaz
    • 1
  • Mesut Ozkaya
    • 1
  • Nurten Aksoy
    • 3
  • Ersin Akarsu
    • 1
  1. 1.Department of Endocrinology, Faculty of MedicineGaziantep UniversityGaziantepTurkey
  2. 2.Department of Biochemistry, Faculty of MedicineGaziantep UniversityGaziantepTurkey
  3. 3.Department of Biochemistry, Faculty of MedicineHarran UniversitySanliurfaTurkey

Personalised recommendations